Acta Neurologica Scandinavica

Papers
(The H4-Index of Acta Neurologica Scandinavica is 23. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
Neurological Manifestations of COVID‐19: A systematic review and current update281
Neurological side effects of SARS‐CoV‐2 vaccinations101
The potential neurological effect of the COVID‐19 vaccines: A review81
Epilepsy in time of COVID‐19: A survey‐based study70
Effect of COVID‐19 pandemic on stroke admission rates in a Norwegian population56
The Non‐Motor Symptoms Scale in Parkinson’s disease: Validation and use52
Efficacy and safety of rituximab in autoimmune encephalitis: A meta‐analysis45
Glymphatic dysfunction in isolated REM sleep behavior disorder34
Neutrophil–lymphocyte ratio in acute ischemic stroke: Immunopathology, management, and prognosis34
Cannabidiol efficacy independent of clobazam: Meta‐analysis of four randomized controlled trials34
Parkinson’s disease and intensive exercise therapy — An updated systematic review and meta‐analysis33
Safety and efficacy of Direct Oral Anticoagulants in cerebral venous thrombosis: A meta‐analysis33
Blood biomarkers for Alzheimer's disease and related disorders30
COVID‐19 presentations and outcome in patients with epilepsy30
In‐hospital acute stroke workflow in acute stroke – Systems‐based approaches30
Neutrophil‐to‐lymphocyte ratio and CRP as biomarkers in multiple sclerosis: A systematic review27
Refractory migraine profile in CGRP‐monoclonal antibodies scenario27
Blood biomarkers in ALS : challenges, applications and novel frontiers27
Neurophysiological impairments in multiple sclerosis—Central and peripheral motor pathways26
Air pollution, a possible risk factor for multiple sclerosis25
Medication adherence/persistence among patients with active multiple sclerosis in Finland24
SARS‐CoV‐2 vaccines are not free of neurological side effects24
Persistent olfactory dysfunction after COVID‐19 is associated with reduced perfusion in the frontal lobe24
0.023776054382324